Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Glioblastoma 60Carcinoma, Non-Small-Cell Lung 48Lung Neoplasms 39Head and Neck Neoplasms 26Gliosarcoma 26Squamous Cell Carcinoma of Head and Neck 25Pancreatic Neoplasms 25Central Nervous System Neoplasms 23Brain Neoplasms 22Rectal Neoplasms 21Breast Neoplasms 17Astrocytoma 17Sarcoma 16Neoplasms 16Glioma 15Uterine Cervical Neoplasms 14Prostatic Neoplasms 14Esophageal Neoplasms 14Carcinoma, Squamous Cell 11Lymphoma, Follicular 10Leukemia 10Melanoma 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 8Neoplasm Metastasis 7Myelodysplastic Syndromes 7Lymphoma, Mantle-Cell 7

Interventions

pembrolizumab 10Docetaxel 8senaparib 7Injections 7Capecitabine 7Paclitaxel 6Cisplatin 6Irinotecan 5Fluorouracil 5Leucovorin 4Cyclophosphamide 4Bevacizumab 4tislelizumab 3pertuzumab 3fludarabine 3atezolizumab 3Rifampin 3Oxaliplatin 3Itraconazole 3Gemcitabine 3ontuxizumab 2navoximod 2fluzoparib 2durvalumab 2Trastuzumab 2Nivolumab 2Midazolam 2Hydroxychloroquine 2Carboplatin 2130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Solid Tumor × Radiotherapy × Clear all
NCT06349837 2026-05-01

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Sichuan University

Phase 1 Recruiting
24 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡